Conor Keane, Business Correspondent

THE MS treatment known as Tysabri, which is expected to generate €1 billion in annual sales for Elan, is expected to be available in Ireland late next year.

ELAN shares tumbled almost 7% in Dublin yesterday after it said it would hold off on releasing data from trials of its Antegren drug.